| Document and Entity Information | 6 Months Ended |
| Dec. 31, 2017USD ($)shares | |
| Document and Entity Information: | |
| Entity Registrant Name | SANGUI BIOTECH INTERNATIONAL INC |
| Document Type | 10-Q |
| Document Period End Date | Dec. 31, 2017 |
| Trading Symbol | sgbi |
| Amendment Flag | false |
| Entity Central Index Key | 1,104,280 |
| Current Fiscal Year End Date | --06-30 |
| Entity Common Stock, Shares Outstanding | shares | 188,451,503 |
| Entity Public Float | $ | $ 188,451,503 |
| Entity Filer Category | Smaller Reporting Company |
| Entity Current Reporting Status | No |
| Entity Voluntary Filers | No |
| Entity Well-known Seasoned Issuer | Yes |
| Document Fiscal Year Focus | 2,018 |
| Document Fiscal Period Focus | Q2 |
| Condensed Consolidated Balance Sheets - USD ($) | Dec. 31, 2017 | Jun. 30, 2017 |
| CURRENT ASSETS | ||
| Cash | $ 18,381 | $ 56,990 |
| Prepaid expenses and other assets | 27,722 | 26,662 |
| Tax refunds receivable | 2,463 | 3,183 |
| Accounts receivable, net | 977 | 468 |
| Note receivable, related party | 7,088 | 6,470 |
| Total Current Assets | 56,631 | 93,773 |
| TOTAL ASSETS | 56,631 | 93,773 |
| CURRENT LIABILITIES | ||
| Accounts payable and accrued expenses | 169,971 | 188,855 |
| Related party payables | 15,874 | 12,214 |
| Note payable | 40,342 | 39,118 |
| Notes payable - related party | 149,754 | 114,109 |
| Total Current Liabilities | 375,941 | 354,296 |
| STOCKHOLDERS' EQUITY (Deficit) | ||
| Common stock, no par value; 250,000,000 shares authorized 188,451,503 and 184,935,259 shares issued and 188,397,747 and 184,881,503 shares outstanding respectively | 32,798,795 | 32,709,868 |
| Additional paid-in capital | 4,513,328 | 4,513,328 |
| Total Stockholders' Equity (Deficit) | (319,310) | (260,523) |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | $ 56,631 | $ 93,773 |
| Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) | 3 Months Ended | 6 Months Ended | ||
| Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | |
| REVENUES | ||||
| Product sales | $ 38,446 | $ 25,797 | $ 55,082 | $ 35,508 |
| COST OF SALES | 40 | 376 | 44 | 658 |
| GROSS MARGIN | 38,406 | 25,421 | 55,038 | 34,850 |
| OPERATING EXPENSES | ||||
| Research and development | 3,176 | 3,908 | 7,805 | 8,328 |
| Professional fees | 54,345 | 129,480 | 93,923 | 169,190 |
| General and administrative | 32,221 | 40,755 | 62,435 | 75,947 |
| Total Operating Expenses | 89,742 | 174,143 | 164,163 | 253,465 |
| OPERATING LOSS | (51,336) | (147,722) | (109,125) | (218,615) |
| OTHER INCOME (EXPENSE) | ||||
| Gain (Loss) of foreign exchange | (1,444) | (5,938) | ||
| Interest expense | (1,053) | (3,776) | (2,835) | |
| Total other income (expense) | (3,352) | (1,053) | (9,714) | (2,835) |
| NET (INCOME) LOSS | $ (54,688) | $ (149,775) | $ (118,839) | $ (221,450) |
| BASIC AND DILUTED WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING | 187,789,962 | 176,861,943 | 187,036,368 | 173,617,871 |
| Condensed Consolidated Statements of Cash Flows | 6 Months Ended | |
| Dec. 31, 2017USD ($) | Dec. 31, 2016USD ($)shares | |
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net loss | $ (118,839) | $ (221,450) |
| Adjustments to reconcile net loss to net cash used by operating activities: | ||
| Common stock issued for services | shares | 9,620 | |
| Gain on change of foreign exchange rates | 6,346 | |
| Changes in operating assets and liabilities | ||
| Trade accounts receivable | $ (476) | $ (170) |
| Prepaid expenses and other current assets | (1,389) | (1,482) |
| Tax refunds receivable | (2,085) | (9,296) |
| Accounts payable and accrued expenses | (24,204) | (1,898) |
| Related parties accounts payable | 3,660 | 38,934 |
| Related party advances | (279) | (470) |
| Net Cash Used in Operating Activities | (133,096) | (186.212) |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Proceeds from related party note payable | 29,299 | |
| Proceeds from common stock issued for cash | 88,928 | 233,950 |
| Net Cash Provided by Financing Activities | 118,277 | 233,950 |
| EFFECTS OF EXCHANGE RATES | (23,740) | (1,683) |
| NET INCREASE (DECREASE) IN CASH | (38,609) | 46,055 |
| CASH AT BEGINNING OF PERIOD | 56,990 | 70,074 |
| CASH AT END OF PERIOD | 18,381 | 116,129 |
| CASH PAID FOR: | ||
| Interest | $ 1,553 | $ 1,542 |
| Note 1 - Basis of Presentation | 6 Months Ended |
| Dec. 31, 2017 | |
| Notes | |
| Note 1 - Basis of Presentation | NOTE 1 - BASIS OF PRESENTATION The accompanying consolidated financial statements have been prepared without audit in accordance with accounting principles generally accepted in the United States of America for interim financial information. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The unaudited consolidated financial statements and notes should, therefore, be read in conjunction with the consolidated financial statements and notes thereto in the Company's Form 10-K for the year ended June 30, 2017. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair presentation, have been included. The results of operations for the three and six months ended December 31, 2017 are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2018. |
| Note 2 - Summary of Significant Accounting Policies | 6 Months Ended |
| Dec. 31, 2017 | |
| Notes | |
| Note 2 - Summary of Significant Accounting Policies | NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Business Sangui Biotech International, Inc., was incorporated in Colorado in 1995, and conducts business through its ninety-percent-owned subsidiary, Sangui BioTech GmbH (Sangui GmbH). Sangui GmbH, which is headquartered in Witten, Germany, is engaged in the development of artificial oxygen carriers (external applications of hemoglobin, blood substitutes and blood additives) as well as in the development, marketing and sales of cosmetics and wound management products. Consolidation The consolidated financial statements include the accounts of Sangui BioTech International, Inc. and its subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation. Foreign Currency Translation Assets and liabilities of the Company's foreign operations are translated into U.S. dollars at period-end exchange rates. Net exchange gains or losses resulting from such translation are excluded from net loss but are included in comprehensive income (loss) and accumulated in a separate component of stockholders' equity. Income and expenses are translated at average exchange rates for the period. Exchanges rates used for the preparation of the consolidated balance sheet as of December 31, 2017 and June 30, 2017 and our unaudited consolidated statements of operations for the three and six month periods ended September 30, 2017 and 2016, were calculated as follows: The Company accounts for the translations denominated in foreign currencies in the Parent Companys books as transaction gains (losses) recognized in General & Administrative expenses. Risk and Uncertainties The Company's line of future pharmaceutical products (artificial oxygen carriers or blood substitute and additives) and medical products (wound dressings and other wound management products) being developed by Sangui GmbH, are deemed as medical devices or biologics, and as such are governed by the Federal Food and Drug and Cosmetics Act and by the regulations of state agencies and various foreign government agencies. The pharmaceutical, under development in Germany, will be subject to more stringent regulatory requirements, because they are in vivo products for humans. The Company and its subsidiaries have no experience in obtaining regulatory clearance on these types of products. Therefore, the Company will be subject to the risks of delays in obtaining or failing to obtain regulatory clearance. Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has accumulated deficit of $ 37,091,180 118,839 133,096 Cash and Cash Equivalents The Company maintains its cash in bank accounts in Germany. Cash and cash equivalents include time deposits for which the Company has no requirements for compensating balances. The Company has not experienced any losses in its uninsured bank accounts. Research and Development Research and development costs are charged to operations as they are incurred. Legal fees and other direct costs incurred in obtaining and protecting patents are expensed as incurred. Revenue Recognition Product sales revenue is recognized when the sales amount is determined, shipment of goods to the customer has occurred and collection is reasonably assured. Product is shipped FOB origination. Product royalty revenue is recognized when the licensee has reported the product sales to the Company. Product royalty revenue is calculated based upon the contractual percentage of reported sales. Basic and Diluted Earnings (Loss) Per Common Share Basic earnings (loss) per common share are computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted earnings (loss) per share give effect to all potential dilutive common shares outstanding during the period of compensation. The computation of diluted earnings (loss) per share does not assume conversion, exercise or contingent exercise of securities that would have an antidilutive effect on earnings. As of December 31, 2017, the Company had no potentially dilutive securities that would affect the loss per share if they were to be dilutive. Comprehensive Income (Loss) Total comprehensive income (loss) represents the net change in stockholders' equity during a period from sources other than transactions with stockholders and as such, includes net earnings (loss). For the Company, the components of other comprehensive income (loss) are the changes in the cumulative foreign currency translation adjustments and unrealized gains (losses) on marketable securities and are recorded as components of stockholders' equity. Reclassifications Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses. Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements. |
| Note 3 - Commitments and Contingencies | 6 Months Ended |
| Dec. 31, 2017 | |
| Notes | |
| Note 3 - Commitments and Contingencies | NOTE 3 - COMMITMENTS AND CONTINGENCIES Litigation The Company may, from time to time, be involved in various legal disputes resulting from the ordinary course of operating its business. Management is currently not able to predict the outcome of any such cases. However, management believes that the amount of ultimate liability, if any, with respect to such actions will not have a material effect on the Company's financial position or results of operations. Indemnities and Guarantees During the normal course of business, the Company has made certain indemnities and guarantees under which it may be required to make payments in relation to certain transactions. These indemnities include certain agreements with the Company's officers, under which the Company may be required to indemnify such person for liabilities arising out of their employment relationship. The duration of these indemnities and guarantees varies and, in certain cases, is indefinite. The majority of these indemnities and guarantees do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not been obligated to make significant payments for these obligations and no liabilities have been recorded for these indemnities and guarantees in the accompanying consolidated balance sheet. |
| Note 4 - Debt | 6 Months Ended |
| Dec. 31, 2017 | |
| Notes | |
| Note 4 - Debt | NOTE 4 DEBT Notes Payable Related Parties Prior to 2016, the Company entered into a note payable with a Company Director for 100,000 Euros ($ 119,804 15,843 On December 12, 2017 a Company Director advanced an amount of 25,000 Euros ($ 29,951 31 Notes payable On June 15, 2015 the Company entered into an unsecured note for 32,963 Euros and accrues interest annually at 4%. The note was originally entered into with a related-party. As of December 31, 2017, due to a change in nature of relationship with the note holder, the Company has discontinued recording it as a related party obligation. As of December 31, 2017, the balance of the note is $ 39,551 777 40,342 |
| Note 5 - Capital Stock | 6 Months Ended |
| Dec. 31, 2017 | |
| Notes | |
| Note 5 - Capital Stock | NOTE 5 CAPITAL STOCK Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock. No preferred stock has been issued so far. The authorized preferred shares are non-voting and the Board of Directors has not designated any liquidation value or dividend rates. Common Stock The Company is authorized to issue 250,000,000 shares of no par value common stock. The holders of the Company's common stock are entitled to one vote for each share held of record on all matters to be voted on by those stockholders. As of December 31, 2017 and June 30, 2017, the Company had 188,451,503 184,935,259 184,881,503 On May 11, 2015, the Company entered into an equity purchase agreement (the EPA) with an unrelated investor (the Investor). The EPA is a put option contract wherein, at the Companys sole discretion, up to $5,000,000 of common stock may be sold to the Investor for a period of 3 years ending May 2018. Under the terms of the EPA, prior to 2016, the Company issued 208,333 shares pursuant to a put notice for $10,000. The put notice yielded $1,500 in cash against 37,037 of the 208,333 shares. In addition to these 37,037 shares, the investor converted $2,973 in accrued interest related to a prior convertible note payable into 165,144 shares, leaving 6,152 shares held by the investor that are receivable by the Company as of December 31, 2017. During the six months ended December 31, 2017, the Company sold 3,570,000 88,927 |
| Note 6 - Subsequent Events | 6 Months Ended |
| Dec. 31, 2017 | |
| Notes | |
| Note 6 - Subsequent Events | NOTE 6 SUBSEQUENT EVENTS In accordance with ASC 855-10, the Companys management has reviewed all material events and there are no additional material subsequent events to report. |
